Omnicare Names GenieRx Stalking Horse Bidder in Court-Supervised Sale Process
Omnicare has entered an asset purchase agreement with GenieRx as the stalking horse bidder in its court-supervised sale process, setting a floor price ahead of an April 30 bid deadline and a May 5 auction. The process continues to maintain transparent pricing and clinical programs aligned with CMS value-based measures.
1. Asset Purchase Agreement
Omnicare entered into an asset purchase agreement with GenieRx Holdings LLC, a joint venture of Milrose Capital and Integro Healthcare Services. Under the agreement, GenieRx will act as the stalking horse bidder, establishing the minimum bid for Omnicare’s long-term care pharmacy assets.
2. Court-Supervised Sale Process and Timeline
The court-supervised sale process sets an April 30, 2026 deadline for competing bids and anticipates an auction on May 5, 2026. A subsequent court hearing will approve the winning bid, allowing offers above GenieRx’s floor price.
3. Ongoing Operations and Customer Focus
Throughout the sale, Omnicare maintains transparent pricing, clinical programs aligned with CMS value-based purchasing measures, and analytics support for ISNPs, ACOs and other risk-bearing models. Assisted living communities continue to receive partnership-driven pharmacy services and improvements to billing and delivery.
4. Potential Implications for CVS Health
The divestiture of Omnicare could reshape CVS Health’s long-term care segment valuation and free up capital for other initiatives. Investors will monitor bid levels and competing offers as indicators of asset value and strategic direction.